Expressional evaluation of vascular endothelial growth factor (VEGF) protein in urinary bladder carcinoma patients exposed to cigarette smoke

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 3, 2012, Pages 195-202

  Rahmani, Arshad ^a,b,c   Alzohairy, Mohammad ^a   Khadri, Habeeb ^a   Mandal, Ashish K ^b   Rizvi, Moshahid A ^c  

^a QASSIM UNIVERSITY   (Saudi Arabia)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Apoptosis and cigarette smoking; Bladder cancer; IHC; TUNEL assay

Indexed keywords

TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE; AGED; APOPTOSIS; ARTICLE; BLADDER TUMOR; CANCER GRADING; CASE CONTROL STUDY; CHEMISTRY; CHI SQUARE DISTRIBUTION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INDIA; MALE; MIDDLE AGED; NICK END LABELING; PATHOLOGY; RISK; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INDIA; MALE; MIDDLE AGED; NEOPLASM GRADING; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84861205345     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Madeb R, Meesing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22: 86-92.
2. Strope SA, Montie JE. The Causal Role of Cigarette Smoking in Bladder Cancer Initiation and Progression, and the Role of Urologists in Smoking Cessation. J Urol 2008; 180: 31-37.
3. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, Schwenn M, Colt JS, Cherala S, Samanic C, Waddell R, Cantor KP, Schned A, Rothman N, Lubin J, Fraumeni JF Jr, Hoover RN, Kelsey KT, Silverman DT. A case-control study of smoking and bladder cancer risk: emergent patterns over time. Journal of the national cancer institute. J Natl Cancer Inst 2009; 101: 1553-1561.
4. Hemelt M, Yamamoto H, Cheng KK, Zeegers MP. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer 2009; 124: 412-419.
5. Zhang ZF, Sarkis AS, Carlos CC, Dalbagani D, Melamed J, Aprikian A, Pollack D, Shaienfold j, Herr HW, Fair WR, Reuter VE, Begg C. Tobacco Smoking, Occupation, and p53 Nuclear Overexpression in Early Stage Bladder Cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 19-24.
6. Zhang ZF, Shu XM, Cordon-Cardo C, Orlow I, Lu ML, Millon TV, Cao PQ, Connolly-Jenks C, Dalbagni G, Lianes P, Lacombe L, Reuter VE, Scher H. Cigarette smoking and chromosome 9 alterations in bladder cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 321-326.
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial vascular factor. Endocr Rev 1997; 18: 4-25.
8. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001; 193: 1005-1014.
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
10. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001; 8: 9-15.
11. Huovinen R, Warri A, Collan Y. Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 1993; 55: 685-691.
12. Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J Pathol 1991; 163: 337-342.
13. Sachs L, Lotem J. Control of programmed cell death in normal and leucemic cells: new implica tion for therapy. Blood 1993; 82: 15-21.
14. Nisreen SA, Mehdi SJ, Alam MS, Ali A, Mandal AK, Gupta S, Singh I, Rizvi MM. PTEN mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients. J Cancer Res Clin Oncol 2012; 138: 103-109.
15. Mehdi SJ, Alam MS, Batra S, Rizvi MM. Allellic loss at 6q25-27, the Parkin tumor suppressor gene locus in cervical carcinoma. Med Oncol 2011; 28: 1520-1526.
16. Szende B, Juhasaz E, Lapis K, Schally AV. Inhibition of two-step urinary bladder carcinogenesis by the somatostalin analogue. RC-160. Urol Res 1992; 20: 383-386.
17. Chan WY, Yew DT. Apoptosis and bcl-2 oncoprotein expression in the human fetal central nervous system. Anat Rec 1998; 252: 165-175.
18. Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J urol 2009; 25: 207-210.
19. Jung I, Messing E. Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression. Cancer Control 2000; 7: 325-334.
20. Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: A retrospective analysis. Gend Med 2008; 5: 385-394.
21. Gangwar R, Mandhani A, Mittal RD. Caspase 9 and Caspase 8 Gene Polymorphisms and Susceptibility to Bladder Cancer in North Indian Population. Ann Surg Oncol 2009; 16: 2028-2034.
22. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. CA. Cancer statistics, 2005. Cancer J Clin 2005; 55: 10-30.
23. Horn EP, Tucker MA, Lambert G, Silverman D, Zametkin D, Sinha R, Hartge T, Landi MT, Caporaso NE. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 529-533.
24. Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB. Risk of bladder cancer by source and type of tobacco exposure: a casecontrol study. Int J Cancer 1989; 44: 622-628.
25. Spruck CH 3rd, Rideout WM 3rd, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, Jones PA. Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 1993; 53: 1162-1166.
26. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL. Vascular Endothelial Growth Factor Is a Predictor of Relapse and Stage Progression in Superficial Bladder Cancer. Cancer Res 1997; 57: 5281-5285.
27. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer. Cancer Res 1995; 55: 510-513.
28. Michaud SE, Dussault S, Groleau J, Haddad P, Rivard A. Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: Role of NO and reactive oxygen species. J Mol Cell Cardiol 2006; 41: 275-284.
29. Fielding S, Short C, Davies K, Wald N, Bridges BA, Waters R. Studies on the ability of smoke from different types of cigarettes to induce DNA single-strand breaks in cultured human cells. Mutat Res 1989; 214: 147-151.
30. Leanderson P, Tagesson C. Cigarette smokeinduced DNA damage in cultured human lung cells: role of hydroxy radicals and endonuclease activation. Chem Biol Interact 1992; 81: 197-208.
31. Muller T. Expression of c-fos in quiescent Swiss 3T3 cells exposed to aqueous cigarette smoke fractions. Cancer Res 1995; 55: 1927-1932.
32. Chang WC, Lee YC, Liu CL, Hsu JD, Wang HC, Chen CC, Wang CJ. Increased expression of iNOS and c-fos via regulation of protein tyrosine phosphorylation and MEK1/ERK2 proteins in terminal bronchiole lesions in the lungs of rats exposed to cigarette smoke. Arch Toxicol 2001; 75: 28-35.
33. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. Arylamine exposures and bladder cancer risk. Mutat Res 2002; 506-507: 21-28.
34. Closas MG, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, Closas RG, Lloreta J, Vinyals GC, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-659.
35. Matullo G, Guarrera S, Sacerdote C, Polidoro S, Davico L, Gamberini S, Karagas M, Casetta G, Rolle L, Piazza A, Vineis P. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14: 2569-2567.
36. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, Wu X. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 2004; 64: 6820-6826.
37. Rizvi MMA, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK. Aberrant promoter methylation and inacivation of PTEN gene in cervical carcinoma from northern Indian population. J Cancer Res Clin Oncol 2011; 137: 1255-1262.
38. Rizvi MMA, Alam MS, Mehdi SJ, Ali A, Batra S. Allelic loss at 10q23.3, the PTEN gene locus in cervical carcinoma from northern Indian population. Pathol Oncol Res 2011; [Epub ahead of print].